Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 63
Retatrutide: the overstimulated side effect
Some retatrutide users report a wired, restless feeling during titration. The cause traces to GLP-1 receptor agonism activating brain sympathetic pathways.
Semax with armodafinil and nicotine
No published study has examined Semax alongside armodafinil or nicotine. Here is what the mechanisms suggest, and why silence is not a safety finding.
Semax and armodafinil: dopamine overlap
No interaction study covers semax, armodafinil and nicotine together. Here is what the pharmacology shows about dopaminergic overlap.
Thymosin β4 and pyroptosis in microglia
A July 2026 cell-culture study reports that thymosin beta-4 lowers pyroptosis markers in BV2 microglia. Here is what that does and does not show.
Tirzepatide in Sweden: import rules
In Sweden, tirzepatide (Mounjaro) is prescription-only and EU-authorised. Importing from outside the EEA requires dispensation and risks customs seizure.
Tirzepatide in Sweden: licence and cost
Mounjaro (tirzepatide) is licensed and prescribable in Sweden but sits outside the high-cost protection scheme. Here is what changed and what patients pay.
BPC-157 and TB-500 for back pain
BPC-157 and TB-500 show tissue-repair effects in animal models, but no human trial has tested either for chronic back pain.
BPC-157 and TB-4 blend: reconstitution math
How to reconstitute a BPC-157 and TB-4 lyophilised blend, what the arithmetic actually means, and why no validated human dose exists for either peptide.
CJC-1295 / Ipamorelin and Sleep Disruption
A CJC-1295 and ipamorelin blend can deepen early sleep and then fragment the rest of the night. The pharmacology of GH pulse timing explains why.
HGH and tesamorelin: reason to combine?
Tesamorelin stimulates the pituitary to release endogenous GH. Exogenous HGH bypasses it entirely. No clinical trial has evaluated the combination.
SOUL trial: HbA1c predicts heart benefit
A July 2026 JCEM analysis of the SOUL trial found oral semaglutide's MACE benefit tracks glycaemic response more than body weight change.
Respiratory safety of weight-loss drugs
A July 2026 ATS meta-analysis of 123 studies finds no added respiratory harm from four major weight-loss drugs, but flags a gap in asthma-specific evidence.